Telehealth Platforms Proliferate in Online GLP-1 Sales, Raising Regulatory Concerns

The rapid expansion of telehealth platforms has allowed a diverse array of entities, including social media influencers and dating apps, to sell GLP-1 weight-loss medications online. This development has prompted regulatory scrutiny and legal challenges, as highlighted in a recent WIRED report.
Companies such as OpenLoop and Fuse Health provide turnkey solutions that enable new entrants to launch virtual clinics quickly. This has led to a surge in online sales of GLP-1 drugs, often without adequate medical oversight. Medvi, for example, reported over $400 million in GLP-1 sales in 2025, despite lacking healthcare professionals on staff.
The FDA has responded by issuing warnings to approximately 30 telehealth companies for misleading marketing practices related to compounded GLP-1 drugs. These warnings, issued on March 3, 2026, emphasized the need for companies to rectify misleading claims or face potential enforcement actions.
Legal challenges have also emerged, with OpenLoop and compounding pharmacy Triad Rx facing a class-action lawsuit for allegedly selling ineffective compounded GLP-1 products. Consumer interest in these drugs is high, with 11% of U.S. adults using GLP-1s obtaining them through online telehealth channels, a sector projected to grow by 24% annually.